Additionally, use of immune checkpoint inhibitors to enhance the T cell function [9] along with transfer of genetically modified or synthetic receptors (chimeric antigen receptor, CAR) in CD8 + T cells [10] have revolutionized treatment of hematological malignancies and personalized cancer treatment options [11]. Here, CD8A is linked to cancer.